Compounds > troglitazone
Page last updated: 2024-11-05

troglitazone and Local Neoplasm Recurrence

troglitazone has been researched along with Local Neoplasm Recurrence in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goss, G1
Demetri, G1

Reviews

1 review available for troglitazone and Local Neoplasm Recurrence

ArticleYear
Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care.
    Surgical oncology, 2000, Volume: 9, Issue:2

    Topics: Chromans; Combined Modality Therapy; Disease Progression; Fatal Outcome; Humans; Liposarcoma; Male;

2000